• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

CPhI Webinar: Trends and Advances in Patient Centric Drug Development - Watch On Demand

cphi-onlineJune 24, 2021

Tag: CPhI , SPI , Drug development

There is an emerging need for patient centric drug development, and in this recent webinar, Donald Loveday, Global Business Development Manager, SPI Pharma and Doug Hovey, Technical Development Manager, North America, SPI Pharma define patient centricity and discuss its impact on the drug development cycle.

They also review the current standard practices in drug development, identify the unmet needs in patient populations that result, and discuss emerging regulatory requirements and the implications for scientists and executives involved in drug development.


Previous:COVID-19 Healthcare Startup Curative Achieves SOC 2 Security Control Compliance

Next:Honeywell Survey Reveals Healthier Buildings Top the List of Back-to-Work Priorities

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

CPhI Webinar: Trends and Advances in Patient Centric Drug Development - Watch On Demand | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Spironolactone CAS No. 52-01-7

Spironolactone CAS No. 52-01-7
2-Bromo-9,9'-spirobifluorene [171408-76-7]

2-Bromo-9,9'-spirobifluorene [171408-76-7]
fenspiride5053--06--5

fenspiride5053--06--5
Dawnsens® M7001 of flash-spinning nonwoven material

Dawnsens® M7001 of flash-spinning nonwoven material
5-Boc-5-aza-spiro(2.3)hexane-1-carboxylic acid

5-Boc-5-aza-spiro(2.3)hexane-1-carboxylic acid
Spironolactone   Tablets 

Spironolactone   Tablets 
2-oxa-6-azaspiro[3,3]heptanes oxalic acid salt

2-oxa-6-azaspiro[3,3]heptanes oxalic acid salt
Spironolactone

Spironolactone
1,3,5-Triazine, 2,4-diphenyl-6-[2-(spiro[9H-fluorene-9,9'-[9H]xanthen]-2'-yl)phenyl]-

1,3,5-Triazine, 2,4-diphenyl-6-[2-(spiro[9H-fluorene-9,9'-[9H]xanthen]-2'-yl)phenyl]-
Trospium chloride

Trospium chloride

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service